Fundamental Interactions of Nanomaterials with Organisms: Reducing Uncertainty With High Content Data

Robert Tanguay Department of Environmental and Molecular Toxicology Environmental Health Sciences Center Oregon Nanoscience and Microtechnologies Institute (ONAMI) - Safer Nanomaterials and Nanomanufacturing Initiative

> •EPA Science to Achieve Results Grant #RD-833320 •NIEHS P30 Environmental Health and Sciences Center •NIEHS #ESES016896








Proactively guide the development of inherently safer nanomaterials

- Identify the physicochemical properties that drive <u>behaviors</u> – take a global view
- Think nanoscience
- Develop predictive "behavioral models" from experimental data.


- Much in common with the small molecule challenge
- One material at a time approach will ultimately fail
- Generalizations cannot be made...yet
- We need (MUCH) more data
- We need paradigm shift in how we assess hazard
- Very little of this data will be directly used for risk assessment.

How a material "behaves" absolutely depends on its physical properties




Goal is to predict these behaviors from inherent properties

Exposures and Biological Responses



Biology is a System that Responds



Adapted from the National Academy Toxicity Testing for the 21st Century Toxicity Pathway: A cellular response pathway that, when sufficiently perturbed, is expected to result in an adverse effect. National Academy Toxicity Testing for the 21st Century


- We need to identify these toxicity pathways
- Determine if NP perturb them

Nanomaterial Biological Assessments Platforms

- In vitro
 - Continuous cell culture system
 - Primary cell culture system
- In vivo
 - Whole animal studies
 - Rodents- slow and expensive
 - Zebrafish
 - Flies and worms non vertebrates

Cell-Based Approaches

- Advantages - quick, easy and cheap



"There are blind spots"

- Different cell-cell interactions cannot be evaluated
- Indirect effects cannot be evaluated
- Cells in culture can only respond using their unique repertoire of expressed gene products – limited potential targets
- Practical problem...what cells do you choose?
- Tremendous potential for missed data
- Need rapid, in vivo model.....

We need to pick up the pace...

But.... High throughput ≠ high content

For example:


If an assay is developed for a specific responses we are biased.....

i.e. Apoptosis, proliferation, ROS, Calcium influx..

Example

- Cultured endothelial cells
- Expose and collect "omics data"

Hundreds of gene expression changes




- Are these gene expression changes related to an adverse outcome? Do they represent an adaptive response?
- What decisions can be made based solely on this information?

Systems Biological Approach - early embryonic development -

Why?


- Generally more responsive to insult... because
 Most dynamic life stage...and the full signaling repertoire is expressed and active, therefore fewer blind spots..
 Highest potential to detect interactions
- If a chemical or nanomaterial is developmentally toxic it must influence the activity of a molecular pathway or process.. i.e. hit or influence a "Toxicity Pathway"
- Use the biological response to identify the "Toxicity Pathway"





- Share many developmental, anatomical, and physiological characteristics with mammals
- Molecular signaling is conserved across species
- Technical advantages of cell culture power of in vivo
- Amenable to rapid whole animal mechanistic evaluations
- Focus on responses, then identity the "Toxicity Pathway" underlying it - immediately relevant

Development Stages of Assessments



Assessing Biological - Nanomaterials Interactions and responses

Tier 1: Toxicity Screening


Toxicity testing whole organisms
 In vivo - zebrafish

<u>Tier 2:</u> Cellular Targets and Distribution


- Defined in vivo
 - Fluorescent nanomateials
 - Targeted assays

Tier 3: Molecular Expression

- Genomic Responses
 - Whole animal gene expression profiles



Toxicity Testing (First Steps)



High Content Tier 1 Endpoints (Assessed between 24 and 120 hpf)

<u>Morphological</u> Malformations

i.e. pericardial edema, yolk sac edema, body axis fin malformations, eye diameter Circulation Heart beat (rate)

Developmental progression Embryo viability

Behavioral spontaneous movement (18-24 hpf) onset and frequency touch response (27 hpf) motility

Automation: To Increase Throughput

Our Recent Technical Advances

- Embryo Production
- Embryo handling
- Microinjections
- Plate reader based assays
- Behavioral assays

Current Needs

- Efficient dissemination of shared materials
- Reduce the randomness of assessments
- Data sharing infrastructure
- Comparative analysis with shared data
- Define mode of actions of responsive NPs
- Develop predictive behavior models
- Test predictive models